John Cochran

CIK: 0001406773

Transaction Breakdown

Open Market Buys (P)1 (25.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (50.0%)

Compensation grants

Other (G, F, J, C, D, …)1 (25.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

AQST

Aquestive Therapeutics, Inc.

Director

N/A

Crestline Lending Solutions, LLC

Officer

Discretionary Trading P&L

Holdings

Transaction History (4 total)

AQST
Aquestive Therapeutics, Inc.
Oct 21, 2026
Other(J)
Direct
62.2K shares-
No ticker
Crestline Lending Solutions, LLC
Jul 24, 2026
Purchase(P)
Direct
7.6K shares at avg. $19.63$150K
AQST
Aquestive Therapeutics, Inc.
Jun 10, 2026
Award(A)
Stock Option (Right to Purchase)
Direct
50.5K shares-
AQST
Aquestive Therapeutics, Inc.
Jun 11, 2025
Award(A)
Stock Option (Right to Purchase)
Direct
42K shares at avg. $3.41-

		Type	Shares	Price		Ownership
Oct 21, 2026	AQST Aquestive Therapeutics, Inc.	Other(J)	62,229	-	$0	Direct
Jul 24, 2026	No ticker Crestline Lending Solutions, LLC	Purchase(P)	7,643	$19.63	$150,034	Direct
Jun 10, 2026	AQST Aquestive Therapeutics, Inc.	Award(A) Stock Option (Right to Purchase)	50,500	-	-	Direct
Jun 11, 2025	AQST Aquestive Therapeutics, Inc.	Award(A) Stock Option (Right to Purchase)	42,000	$3.41	-	Direct

1-4 of 4 transactions

About Cochran John

Cochran John (SEC CIK 0001406773) files insider reports with the SEC as Director of Aquestive Therapeutics, Inc. (AQST) and Chief Operating Officer of Crestline Lending Solutions, LLC.

Signal8 holds 5 ownership filings by Cochran John (1 Form 3, 4 Form 4), filed between Jun 12, 2025 and Oct 23, 2026. Those filings report 4 transactions, from Jun 11, 2025 to Oct 21, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Cochran John's filings is in WARREN, NJ.

Recent filings by Cochran John

Oct 21, 2026: Other transaction of AQST shares (Form 4, code J).
Jul 24, 2026: Open-market purchase of Crestline Lending Solutions, LLC shares (Form 4, code P).
Jun 10, 2026: Grant or award of AQST derivative securities (Form 4, code A).
Jun 11, 2025: Grant or award of AQST derivative securities (Form 4, code A).

Other insiders filing for Aquestive Therapeutics, Inc. (AQST)

Barber Daniel, President and CEO
Daly Richard J, Director
Korczynski Sherry, Chief Commercial Officer
Boyd Peter E., Chief People Officer
Jung Cassie, Chief Operating Officer
Krop Julie, Director

How to read Form 4 transaction codes